Financials Bio-Works Technologies AB

Equities

BIOWKS

SE0007387089

Medical Equipment, Supplies & Distribution

Delayed Nasdaq Stockholm 09:22:37 2024-05-06 am EDT 5-day change 1st Jan Change
2.8 SEK -1.75% Intraday chart for Bio-Works Technologies AB -4.76% -60.56%

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 176.7 243.9 276.8 959 736.4 276.8
Enterprise Value (EV) 1 122.7 167.5 243.7 856.3 670.6 237.4
P/E ratio -4.64 x -5.76 x -6.15 x -66.3 x -16.4 x -4.51 x
Yield - - - - - -
Capitalization / Revenue 26.9 x 43.8 x 38.3 x 17 x 17.8 x 6.3 x
EV / Revenue 18.7 x 30.1 x 33.7 x 15.2 x 16.2 x 5.41 x
EV / EBITDA -3.86 x -4.01 x -5.36 x -81.8 x -14.4 x -4.17 x
EV / FCF -5.31 x -6.58 x -8.96 x -104 x -26.3 x -6.09 x
FCF Yield -18.8% -15.2% -11.2% -0.96% -3.81% -16.4%
Price to Book 2.87 x 2.97 x 7.39 x 8.84 x 10.9 x 6.29 x
Nbr of stocks (in thousands) 19,336 30,416 30,416 34,874 35,069 38,980
Reference price 2 9.140 8.020 9.100 27.50 21.00 7.100
Announcement Date 4/26/19 4/28/21 4/28/21 4/27/22 4/28/23 4/22/24
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 6.563 5.572 7.234 56.36 41.32 43.9
EBITDA 1 -31.81 -41.75 -45.5 -10.47 -46.67 -56.89
EBIT 1 -33.51 -42.13 -45.65 -10.96 -47.14 -57.5
Operating Margin -510.56% -756.07% -631.1% -19.44% -114.09% -131%
Earnings before Tax (EBT) 1 -37.96 -42.11 -45.02 -9.37 -44.7 -54.73
Net income 1 -37.96 -42.11 -45.02 -12.94 -44.95 -56.82
Net margin -578.32% -755.8% -622.33% -22.96% -108.79% -129.44%
EPS 2 -1.970 -1.392 -1.480 -0.4147 -1.284 -1.573
Free Cash Flow 1 -23.09 -25.46 -27.21 -8.227 -25.53 -38.97
FCF margin -351.83% -456.93% -376.1% -14.6% -61.79% -88.78%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 4/26/19 4/28/21 4/28/21 4/27/22 4/28/23 4/22/24
1SEK in Million2SEK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 S2 2021 S1 2022 S1 2022 S2
Net sales 1 3.541 8.288 - 23.18
EBITDA 1 - 9.6 - -22.04
EBIT 1 - 9.256 - -22.31
Operating Margin - 111.68% - -96.25%
Earnings before Tax (EBT) 1 - - - -21.36
Net income 1 - - -23.53 -21.49
Net margin - - - -92.75%
EPS -0.7900 - -0.6700 -
Dividend per Share - - - -
Announcement Date 2/19/21 8/20/21 8/19/22 2/17/23
1SEK in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 54.1 76.4 33.1 103 65.9 39.4
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -23.1 -25.5 -27.2 -8.23 -25.5 -39
ROE (net income / shareholders' equity) -47.2% -58.6% -75.3% -17.7% -51% -102%
ROA (Net income/ Total Assets) -24.3% -33.9% -42.7% -8.23% -27.7% -46.7%
Assets 1 156.5 124.3 105.3 157.2 162.1 121.6
Book Value Per Share 2 3.190 2.700 1.230 3.110 1.930 1.130
Cash Flow per Share 2 2.800 2.510 1.090 2.950 1.870 1.010
Capex 1 0.78 0.22 0.33 0.94 1.12 0.86
Capex / Sales 11.9% 3.95% 4.51% 1.67% 2.72% 1.96%
Announcement Date 4/26/19 4/28/21 4/28/21 4/27/22 4/28/23 4/22/24
1SEK in Million2SEK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. BIOWKS Stock
  4. Financials Bio-Works Technologies AB
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW